ANP1
Sensorineural Hearing Loss
PreclinicalActive
Key Facts
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel, allogeneic cell therapies for unmet medical needs in neurology, oncology, and ophthalmology. Its core strategy is built on the proprietary AlloSCOPE™ platform, which enables the directed differentiation of pluripotent cells into scalable, 'off-the-shelf' therapeutic products. Recent achievements include a significant collaboration with Genentech for retinal programs and advancing its lead candidate, OPC1, for spinal cord injury. The company aims to validate its platform through clinical milestones and strategic partnerships to address large, underserved markets.
View full company profileTherapeutic Areas
Other Sensorineural Hearing Loss Drugs
| Drug | Company | Phase |
|---|---|---|
| Lead Cell Therapy Program | Rinri Therapeutics | Phase 1 |
| Rinri Therapeutics Collaboration | Mytos | Pre-clinical/Clinical |
| LY3885125 (AK-OTOF) | Eli Lilly | Phase 1/2 |